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ABSTRACT Human norovirus (HuNoV) is a major cause of nonbacterial gastroenteri-
tis worldwide, yet despite its impact on society, vaccines and antivirals are currently
lacking. A HuNoV replicon system has been widely applied to the evaluation of anti-
viral compounds and has thus accelerated the process of drug discovery against
HuNoV infection. Rupintrivir, an irreversible inhibitor of the human rhinovirus 3C
protease, has been reported to inhibit the replication of the Norwalk virus replicon
via the inhibition of the norovirus protease. Here we report, for the ﬁrst time, the
generation of rupintrivir-resistant human Norwalk virus replicon cells in vitro. Se-
quence analysis revealed that these replicon cells contained amino acid substitutions
of alanine 105 to valine (A105V) and isoleucine 109 to valine (I109V) in the viral pro-
tease NS6. The application of a cell-based ﬂuorescence resonance energy transfer
(FRET) assay for protease activity demonstrated that these substitutions were in-
volved in the enhanced resistance to rupintrivir. Furthermore, we validated the ef-
fect of these mutations using reverse genetics in murine norovirus (MNV), demon-
strating that a recombinant MNV strain with a single I109V substitution in the
protease also showed reduced susceptibility to rupintrivir. In summary, using a com-
bination of different approaches, we have demonstrated that, under the correct con-
ditions, mutations in the norovirus protease that lead to the generation of resistant
mutants can rapidly occur.
KEYWORDS antiviral agents, drug resistance mechanisms, noroviruses, protease
inhibitors, proteases
Human norovirus (HuNoV), a member of the Caliciviridae family, represents a majorcause of acute viral gastroenteritis worldwide in both children and adults (1, 2).
HuNoV infection can lead to severe dehydration and diarrhea, especially in the elderly
or immunocompromised patients (3). The considerable economic burden incurred as a
result of norovirus infections, which includes productivity losses and the burden on
health care systems, highlights that HuNoV infection is a global economic problem (4).
Although there is a signiﬁcant unmet medical need for the prevention and treatment
of HuNoV infection, no licensed vaccines or antivirals for HuNoV infection are currently
available. The lack of a robust cellular system for the analysis of viral replication has
hampered antiviral research against HuNoV infection for many years (5). This situation
has been changed by the recent development of enterocytes derived from stem cell
and B cell culture systems (6, 7). Proof of concept that these cell culture systems enable
the evaluation of the antiviral effects of compounds against HuNoV has recently been
demonstrated (8), but neither of these systems is suitable for large-scale screening of
therapeutic compounds. In contrast, while replicon cells lack many features of an
authentic viral life cycle because the viral capsid protein has been replaced with a drug
resistance marker, they have been widely used for the evaluation of the activities of
antivirals against HuNoV (9–11).
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HuNoV belong to three genogroups, genogroup I (GI), GII, and GIV, which are further
subdivided into numerous genotypes, and GII genotype 4 (GII.4) norovirus strains have
been circulating worldwide since 2012 (12, 13). Murine norovirus (MNV) is included in
GV of norovirus (14). The HuNoV genome is composed of three open reading frames
(ORFs). ORF1 encodes the nonstructural polyprotein, which is cleaved into at least six
proteins and several stable intermediates by the viral protease NS6 (15). ORF2 and ORF3
encode the major capsid protein VP1 and the minor capsid protein VP2, respectively.
HuNoV, similar to other RNA viruses, has a high mutation rate that allows rapid viral
evolution due to the error-prone nature of the viral RNA-dependent RNA polymerase
(16, 17). This potentially permits the emergence of drug-resistant viruses during the
course of treatment. In order to overcome this, the development of antiviral drugs for
HuNoV infection requires both potent antiviral activity and a high genetic barrier to the
generation of drug-resistant viruses, especially during treatment for persistent infection
in immunocompromised patients. Information on drug resistance would facilitate drug
design and would be useful for predicting and suppressing the appearance of drug-
resistant viruses. To date, however, the efﬁciency with which resistance occurs and the
mechanisms by which resistance to inhibitors might arise have yet to be described for
any inhibitors against HuNoV. Therefore, we sought to examine whether resistant
replicons could be identiﬁed following prolonged culture in the presence of a suitable
antiviral. To achieve this aim, we utilized rupintrivir (AG7088), an irreversible inhibitor
of the human rhinovirus (HRV) 3C protease. Rupintrivir has been reported to inhibit the
replication of the Norwalk virus replicon in the hepatocellular carcinoma cell line Huh-7,
but whether resistance can be generated remained to be determined (10). In the
present study, we isolated replicon cells with reduced susceptibility to rupintrivir after
several passages in the presence of rupintrivir and identiﬁed two amino acid substitu-
tions of alanine 105 to valine (A105V) and isoleucine 109 to valine (I109V) in the viral
protease. Moreover, we demonstrated that these substitutions are involved in suscep-
tibility to rupintrivir using a previously described cell-based ﬂuorescence resonance
energy transfer (FRET) assay (18). Finally, we determined that recombinant MNV with a
single I109V substitution in the protease showed reduced susceptibility to rupintrivir in
cell culture. We concluded that mutations around the norovirus protease active site
lead to the generation of rupintrivir resistance; however, some of these mutations
appear to compromise viral ﬁtness, at least in the context of the MNV infection model.
RESULTS
Selection of norovirus replicon cells with reduced susceptibilities to rupintrivir
in vitro. To conﬁrm the previously reported inhibitory effects of rupintrivir on human
norovirus replication (10), we generated a human gastric adenocarcinoma cell line,
HGT-NV, which stably maintained a Norwalk virus replicon encoding the neomycin
resistance gene in place of the major capsid protein. The effects of rupintrivir on
norovirus RNA replication in the replicon cells were evaluated by quantitative reverse
transcription-PCR (qRT-PCR). Rupintrivir reduced the levels of replicon in a dose-
dependent manner with a 50% effective concentration (EC50) value of 1.3 0.1 M and
showed low cytotoxicity (50% cytotoxic concentration [CC50], 100 M), which gave a
calculated selectivity index (CC50/EC50) of 77 (Fig. 1A). To determine the concentra-
tion of rupintrivir sufﬁcient to completely eliminate the norovirus replicon from HGT-NV
cells, we treated the replicon cells with 2.5, 5, and 10 M rupintrivir in the absence of
G418 for up to 12 days. The replicon cells were passaged on days 3, 8, and 12, and the
levels of replicon RNA were quantiﬁed by qRT-PCR. A rapid reduction of replicon RNA
levels was observed in the cells treated with 10 M rupintrivir (Fig. 1B). In addition, the
levels of replicon from cells treated with either 5 or 10 M rupintrivir were decreased
to below the limit of quantiﬁcation by 12 days posttreatment. To further characterize
the inhibitory effects of rupintrivir, we performed a colony formation assay with
replicon cells treated with rupintrivir for 12 days. After 1 week of culture without
rupintrivir but with G418 (1.5 mg/ml), the colonies were stained (Fig. 1C). Rupintrivir
treatment reduced the number of colonies in a dose-dependent manner. Treatment
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with 10 M rupintrivir was sufﬁcient to completely prevent colony formation, while
some colonies remained when cells were treated with 2.5 or 5 M rupintrivir.
Given the potent effects of rupintrivir on HGT-NV cells, we sought to determine
whether rupintrivir-resistant replicons could be generated. To this end, HGT-NV cells
were treated with 5 M rupintrivir for 12 days in the absence of G418 selection,
followed by subsequent passages in the presence of G418 with increasing concentra-
tions of rupintrivir for up to 45 days (Fig. 1D). This approach yielded three lineages of
replicon cells which were resistant to 10, 15, and 20 M rupintrivir. To identify the
mutations conferring the resistance to rupintrivir, we isolated cell clones by limiting
dilution using replicon cells surviving after 45 days of culture and then evaluated the
rupintrivir sensitivity of the replicon cells. In comparison to replicon cells that had been
passaged in parallel in the presence of dimethyl sulfoxide (DMSO) alone and that had
an EC50 of 1.3  0.2 M, rupintrivir-resistant replicon cells showed approximately 4- to
11-fold reduced sensitivity to rupintrivir, with EC50s of 5.9 1.3 to 14.3 1.7 M (Table
1). Replicon cells treated with 20 M rupintrivir exhibited the highest levels of resis-
tance compared with those treated with 10 or 15 M rupintrivir. Sequence analyses of
FIG 1 Isolation of rupintrivir-resistant HGT-NV replicon cells. (A) Dose-response curve of effect of rupintrivir on HuNoV replicon
RNA levels in HGT-NV cells. The level of replicon RNA in HTG-NV cells treated with DMSO or rupintrivir was measured by
quantitative RT-PCR. Inhibition was plotted as a percentage relative to that in DMSO-treated cells. Error bars represent means 
standard deviations from three independent experiments. (B) Reduction in the GI replicon RNA level over time in HGT-NV cells
treated with rupintrivir in the absence of G418. The levels of HuNoV replicon RNA relative to those observed in control
DMSO-treated cells were plotted. Error bars represent means  standard deviations from three biological replicates. Dashed
line, detection limit for replicon RNA. (C) Colony formation assays with HGT-NV cells treated with DMSO or rupintrivir for 12
days. Colonies were stained and photographed on day 7 after treatment with G418 (1.5 mg/ml) in the absence of rupintrivir.
(D) Schematic overview of the procedure used for the repetitive cultivation of HGT-NV cells in the presence of increasing
concentrations of rupintrivir. HGT-NV cells were maintained as subconﬂuent cultures in the presence of DMSO or rupintrivir
and G418 and passaged every 2 to 3 days for 45 days.
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the NS6 protease region of the replicon from the resistant clones revealed two amino
acid substitutions: alanine 105 to valine (A105V) and isoleucine 109 to valine (I109V). All
clones treated with 10 M rupintrivir had the I109V single amino acid substitution,
while the A105V/I109V double amino acid substitution was observed only in clones
treated with 15 and 20 M rupintrivir. The A105V single amino acid substitution alone
was not observed in any of the clones sequenced.
Mutations conferring resistance to rupintrivir map to positions near the noro-
virus protease active site. An amino acid sequence alignment of HuNoV GI and GII
and MNV GV conﬁrmed that A105 and I109 are highly conserved (Fig. 2A). To gain a
better understanding of the mechanism by which these mutations might affect rupin-
trivir binding, we examined the published crystal structures of the GI protease in
complex with a peptidyl inhibitor (PDB accession number 2IPH) as well as the GV
protease (PDB accession number 4ASH) (19, 20). Analysis of the protease structure
revealed that I109 is positioned near the S2 and S4 pockets of the protease (Fig. 2B),
regions of the protease that are involved in hydrophobic and van der Waals interactions
with the P2 and P4 residues of a substrate or inhibitor (19, 21). A previous mutagenesis
study has also suggested that the mutation of I109 affects the binding of the P2 and
P4 residues of the substrate (22). The mutations identiﬁed here appear to be somewhat
similar to those identiﬁed in a rupintrivir-resistant poliovirus (PV) strain which had
single amino acid substitution, G128Q, in a ﬂexible loop (PDB accession number 4DCD;
Fig. 2B) (23, 24) and also in a rupintrivir-resistant HRV2 strain which had the N165T
substitution in the S4 pocket (PDB accession number 1CQQ; Fig. 2B) (25, 26). We
therefore modeled the interaction of the GI and GV proteases with rupintrivir based on
the crystal structure of the HRV2 3C protease with rupintrivir (26) (Fig. 2C). These
structural alignments suggested that a change in hydrophobicity associated with the
I109V mutation could, in principle, result in the reduced susceptibility of protease to
rupintrivir, an effect similar to that caused by the G128Q mutation in rupintrivir-
resistant PV protease (Fig. 2C). In contrast, the A105V mutation showed no obvious
interactions with rupintrivir in these alignments; however, the possibility of allosteric
effects could not be ruled out.
The mutations I109V and A105V affect the susceptibility to rupintrivir in a
cell-based FRET assay. Our ﬁndings supported the hypothesis that the amino acid
positions I109 and A105 could directly or indirectly affect the susceptibility of the viral
protease to rupintrivir. To address this hypothesis, we utilized our previously described
cell-based FRET assay, which enables the detection of norovirus protease activity in live
cells (18). We ﬁrst sought to examine the impact of the substitutions on the cleavage
activity of the viral protease from each genogroup. Therefore, we constructed three
mutants, the A105V, I109V, and A105V/I109V mutants, with mutations in each of the GI,
TABLE 1 Susceptibility of HGT-NV cells to rupintrivir after repetitive cultivation
Rupintrivir concn
(M) at ﬁnal passage
or control treatment
Clone
no.
Mean EC50  SDa
(M)
Fold change in
sensitivityb
Amino acid
substitution(s) in
protease
20 1 14.3 1.7 10.9 A105V/I109V
2 12.3 1.2 9.4 A105V/I109V
3 15.3 1.1 11.7 A105V/I109V
15 1 8.5 1.9 6.5 A105V/I109V
2 14.3 1.3 10.9 A105V/I109V
3 6.9 1.7 5.3 I109V
10 1 6.6 2.4 5.0 I109V
2 6.3 2.3 4.8 I109V
3 5.9 1.3 4.5 I109V
DMSO 1.3 0.2 1.0
aThe EC50s are the means  standard deviations from three independent experiments.
bFold change in sensitivity relative to that achieved with DMSO.
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GII, and GV proteases. For the FRET substrate, we chose the NS1/2-NS3 cleavage site
from the homologous genogroup because our prior study demonstrated that this site
was efﬁciently cleaved by the GI, GII, and GV proteases (18). As expected, a FRET signal
was detected in HEK293T cells transfected with the FRET substrate and the empty
vector (EV) or an inactive protease which had a H30A substitution in the catalytic site
(Fig. 3A). Each mutant protease of all genogroups showed cleavage activity comparable
to that of the wild-type (WT) protease. To examine whether the loss of the FRET signal
FIG 2 Amino acid sequence alignment and structural comparison of norovirus proteases. (A) Amino acid sequence alignment of the GI (GenBank accession
number M87661), GII (GenBank accession number DQ658413), and GV (GenBank accession number DQ285629) proteases used in this study. Identical amino
acids (in black) are highlighted. Black arrowheads, positions of the amino acids where substitutions were observed in rupintrivir-resistant replicon cells. (B)
Crystal structures of the GI Southampton norovirus protease in complex with a peptidyl inhibitor (gray) (PDB accession number 2IPH) (19) and the GV MNV
protease (PDB accession number 4ASH) (20). Residues A105 and I109 in the GI and GV proteases are indicated in red. The crystal structures of poliovirus (PV)
protease in complex with GC376 (blue) (PDB accession number 4DCD) (24) and human rhinovirus 2 (HRV2) protease in complex with rupintrivir (cyan) (PBD
accession number 1CQQ) (26) are also shown. Residue G128 in the PV protease and residues N165, E3, and A103 in the HRV2 protease, involved in rupintrivir
resistance, are indicated in red (23, 25). The catalytic residues C139 (GI), A139 mutated from cysteine (GV), C147 (PV), and C147 (HRV2) are indicated in orange.
(C) The crystal structure of the GI, GV, or PV protease was aligned to the HRV2 protease crystal structure in complex with rupintrivir and shown as the
hydrophobic surface of each protease with rupintrivir (cyan). Residues A105 and I109 in the GI and GV protease and residue G128 in the PV protease are
indicated in red.
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FIG 3 Inhibitory effects of rupintrivir on the mutant proteases in a cell-based FRET assay. (A) The FRET signal from a sensor
(YFP/CFP ratio) was lost upon cotransfection with WT or mutant protease but not with the inactive (H30A) protease and the
empty vector (EV). The GI, GII, and GV mutant proteases showed cleavage activity comparable to that of the wild type (WT).
(B) Western blot analysis of HEK293T cells cotransfected with the GI, GII, or GV NS1/2-NS3 FRET sensor along with either the
WT or mutant proteases. Similar cleavage products corresponding to CFP and YFP were observed in the WT and mutant
proteases in all genogroups. MM, molecular mass. (C) Dose-response inhibition curves showing the effect of rupintrivir on
either the WT or mutant proteases of GI, GII, and GV genotypes in the cell-based FRET assay. (D) IC50s of rupintrivir along with
the standard deviations of the means from three independent experiments. Asterisks indicate statistically signiﬁcant differ-
ences, as follows: *, P  0.05; **, P  0.01; ***, P  0.001. Abbreviation: n.s., not signiﬁcant.
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represented cleavage of the substrate, we performed Western blotting analyses on
samples transfected with the FRET substrate and protease. Similar cleavage products
corresponding to cyan ﬂuorescent protein (CFP) and yellow ﬂuorescent protein (YFP)
were observed in all genogroups (Fig. 3B), conﬁrming that the mutations did not have
any overt impact on overall protease activity per se. Next, we evaluated the inhibitory
effects of rupintrivir on WT and mutant proteases in the FRET assay. The GI WT protease
was inhibited by rupintrivir in a dose-dependent manner with a 50% inhibitory con-
centration (IC50) value of 1.3 0.4 M, similar to that seen in the replicon cells (Fig. 3C).
In comparison to GI WT protease, a signiﬁcant reduction in susceptibility to rupintrivir
was observed in the GI A105V, I109V, and the A105V/I109V mutant proteases, with IC50s
of 4.2  1.1 (3.2-fold increase), 4.0  0.4 (3.1-fold increase), and 6.6  1.2 M (5.1-fold
increase), respectively (Fig. 3D). In addition, signiﬁcant differences were observed when
the GI A105V and I109V single mutants were compared with the A105V/I109V double
mutant, suggesting that, at least in the context of the GI protease, these substitutions
have an additive effect on susceptibility to rupintrivir. In contrast, when the substitu-
tions were introduced into the GII protease, they had no measurable effect on the IC50
and only a small, but signiﬁcant, effect on the GV protease. The GV WT protease showed
an IC50 of 1.0  0.1 M, whereas only the mutant proteases with the I109V single
substitution and the A105V/I109V double substitution had reduced susceptibility to
rupintrivir, with IC50s of 2.7  0.6 (2.7-fold increase) and 2.3  0.3 M (2.3-fold
increase), respectively.
Recombinant MNV containing a single I109V substitution in NS6 showed
reduced susceptibility to rupintrivir. To examine the impact of the rupintrivir resis-
tance mutations in the context of authentic viral replication, we introduced the single
mutations A105V and I109V as well as the double mutation A105V/I109V into a
full-length infectious MNV-1 cDNA clone (27). To conﬁrm that the introduced mutations
had no overt impact on protease activity when expressed in the context of the viral
polyprotein, we examined the impact of the mutations on viral polyprotein processing
in vitro. To this end, we generated in vitro-transcribed, capped RNA transcripts from the
WT MNV-1 cDNA clone or clones carrying the rupintrivir resistance mutations and
examined their translation proﬁles in rabbit reticulocyte lysates. We found that the
processing of the mutants was largely indistinguishable from that of the WT virus (Fig.
4). Furthermore, we demonstrated that the resistance to rupintrivir was maintained
when the protease was expressed from the polyprotein as the I109V single mutant, and
the A105V/I109V double mutant was still able to produce mature NS3 at a concentra-
tion that prevented the cleavage of the polyprotein by the WT protease (Fig. 4).
To examine the impact of the mutations on viral resistance to rupintrivir, we used
the cDNA clones to generate recombinant viruses following transfection of cells
expressing T7 RNA polymerase. The WT and I109V recombinant viruses were success-
fully recovered in BSR-T7 cells, while the A105V and A105V/I109V recombinant viruses
were nonviable (Fig. 5A). As we have previously demonstrated that RNA-mediated
reverse genetics can improve the yield of recovered viruses, particularly those with
reduced ﬁtness (28), we also examined the ability of in vitro-transcribed and capped
RNA to generate recombinant virus. As expected, the virus yield observed for the WT
and I109V recombinant viruses was signiﬁcantly higher than that obtained using a
DNA-based reverse genetics system, while the A105V and A105V/I109V viruses re-
mained nonviable (Fig. 5B). Since there is a possibility that the recombinant viruses with
A105V replicate without inducing a cytopathic effect, which is used as the basis of the
infectivity titration assay, we measured the levels of viral RNA in samples by qRT-PCR
after three passages in culture. Despite repeated passage, we found no signs of viral
RNA replication from the A105V and A105V/I109V recombinant viruses (Fig. 5C). These
results suggest that amino acid residue A105 plays a critical role in virus replication in
the MNV strain used in this study.
The impact of the introduced mutations on viral replication in the absence of
rupintrivir was analyzed by comparing the viral growth kinetics of the WT and I109V
recombinant viruses at various multiplicities of infection (MOIs) of 0.1, 1, and 10 50%
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tissue culture infective doses (TCID50)/cell (Fig. 6A). The replication of the I109V
recombinant virus was indistinguishable from that of the WT virus at all the MOIs
studied. Furthermore, sequence analysis indicated that the I109V recombinant virus
was genetically stable, even after multiple passages in cell culture. We then evaluated
the inhibitory effects of rupintrivir and, as a control, the nucleoside viral polymerase
inhibitor 2-C-methylcytidine (2CMC), against the WT and I109V recombinant viruses.
Signiﬁcant differences in viral titers following treatment with 10 and 20 M rupintrivir
were observed between the WT and I109V recombinant viruses at two MOIs (Fig. 6B).
In addition, a small, but signiﬁcant, reduction in the susceptibility of the I109V virus to
rupintrivir was shown at MOIs of 0.1 and 1 TCID50/cell, with the EC90s increasing from
FIG 4 Impact of rupintrivir resistance-conferring mutations on MNV polyprotein processing in vitro. In
vitro translation reactions were programmed with equal quantities of in vitro-transcribed MNV full-length
capped RNA containing either the WT or mutant proteases in the presence and absence of 80 M
rupintrivir. The [35S]methionine-labeled products were subsequently analyzed by SDS-PAGE and phos-
phorimaging analysis. The percentage of fully processed NS3, determined on the basis of the expected
molecular mass of the proteins, was calculated and expressed relative to the total amount of viral protein
produced.
FIG 5 Impact of rupintrivir resistance-conferring mutations on the recovery of recombinant MNV. (A and B)
Virus titers obtained at 24 h after transfection of BSR-T7 cells with MNV cDNA (A) or in vitro-transcribed and
capped MNV RNA (B). The virus titers in BV-2 cells were determined by the TCID50 method. Error bars
represent means  standard deviations from three independent experiments. Dotted lines, detection limit
of the assay. (C) The increase in the RNA level (the RNA level at 12 h postinoculation minus the RNA level
at 1 h postinoculation) was determined by qRT-PCR after three passages with BV-2 cells. The supernatant
of BSR-T7 cells transfected with MNV cDNA was inoculated onto BV-2 cells. At 48 h postinoculation, the
supernatant of BV-2 cells was next inoculated onto BV-2 cells. This passage was repeated two times. After
three passages, the supernatant was inoculated onto BV-2 cells and the increase in the RNA level was
measured. No increase in the amount of viral RNA of the A105V and A105V/I109V recombinant viruses was
observed.
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9.1 to 18.1 M (2.0-fold increase; P  0.001) and 8.9 to 17.0 M (1.9-fold increase; P 
0.001), respectively. There was no signiﬁcant difference in the EC90 values for 2CMC
between the I109V and WT viruses. These results demonstrate that the I109V substi-
tution alone is sufﬁcient to impact susceptibility to rupintrivir in the context of the MNV
protease.
DISCUSSION
Currently, there are no antiviral drugs for HuNoV, and as such, antiviral-resistant
mutants of HuNoV have yet to pose a major clinical problem. However, a better
understanding of the mechanisms of resistance to various classes of antiviral drugs is
critical for developing ways of minimizing the appearance of resistance. The lack of a
robust culture system for HuNoV has severely limited the development of therapeutic
approaches, but with the recent discovery of the B cell and enteroid culture systems,
this bottleneck now appears to have been overcome. Despite this, to date, most studies
have relied on the use of a replicon-based approach due to the scalability and the
robust nature of the assay. However, the mechanism by which drug resistance may
occur in HuNoV has yet to be described. In the present study, we successfully generated
a replicon system in a physiologically relevant cell line, namely, human gastric tumor
cells (29). This was then used to isolate replicon cells with reduced susceptibility to
rupintrivir. The EC50 and CC50 values of rupintrivir in the HGT-NV replicon system were
1.3  0.1 M and 100 M, respectively, which were comparable to those presented
in a previous report describing a study with an HG23 cell system based on the same
FIG 6 The I109V substitution in the MNV protease results in reduced susceptibility to rupintrivir during viral replication in cell culture.
(A) The growth kinetics of the WT and I109V recombinant MNV were assessed following infection of BV-2 cells at MOIs of 0.1, 1, and
10 TCID50/cell. Viral infectivity levels were determined by measuring the release of infectious virus into the culture supernatant at
various times postinfection by determination of the TCID50. (B) The inhibitory effects of rupintrivir and 2CMC against either the WT
or the recombinant MNV I109V mutant were assessed following infection of BV-2 cells at MOIs of 0.1 and 1 TCID50/cell. A signiﬁcant
difference in viral titers following treatment with 10 and 20 M and 10, 20, and 40 M rupintrivir was observed between the WT and
I109V recombinant viruses at MOIs of 0.1 and 1, respectively (*, P  0.05; **, P  0.01; ***, P  0.001). In contrast, there were no
signiﬁcant differences in virus titers following treatment with 2CMC.
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replicon in the Huh-7 hepatocellular carcinoma cell line (24). The inhibitory effects and
the high selectivity index (CC50/EC50) of 77 were considered sufﬁcient to perform the
resistance study. Repeated cultivation of the replicon cells for 45 days in the presence
of rupintrivir resulted in the selection of two amino acid substitutions, I109V and
A105V/I109V, in GI protease. The precise time during the culture period when a
mutation ﬁrst arose was not identiﬁed in this study, as the goal was to simply identify
mutations that conferred high levels of resistance to rupintrivir. The mutant with the
double amino acid A105V/I109V substitution showed a tendency to be less susceptible
to rupintrivir than the mutant with the I109V single amino acid substitution (Table 1).
Similar features of resistance have been reported in an in vitro study with rupintrivir-
resistant HRV2 (25). Serial passage of HRV2 for 62 days resulted in the single amino acid
substitution N165T and double amino acid substitutions (N165T/E3G or N165T/A103V),
and the mutants with these substitutions showed 2- and 5-fold reduced susceptibility
to rupintrivir, respectively. In general, the resistance to protease inhibitors typically
involves the accumulation of primary and secondary mutations that are located within
and outside the active site of protease (30, 31). Although the process of accumulation
of mutations was not clariﬁed in this study, on the basis of the observation that the
A105V substitution was not identiﬁed in isolation, it is presumed that it arose as a
secondary mutation that can cause increased levels of resistance and/or compensate
for some reduced functionality of the protease.
Amino acid sequence alignment revealed that A105 and I109 are absolutely con-
served in the GI, GII, and GV genogroups (Fig. 2A). These amino acid positions were also
conserved in the HuNoV GIV genogroup, which is rarely detected, whereas the bovine
norovirus GIII and canine norovirus GVI genogroups had T105 and V109 in the viral
protease and A105 and V109 in the viral protease, respectively (data not shown). Using
a cell-based FRET assay with mutant proteases from the GI, GII, or GV genogroup, we
demonstrated that the mutant proteases had proteolytic activity on an NS1/2-3 cleav-
age site-based substrate equivalent to that of the WT protease (Fig. 3A and B). We
elucidated that the GI I109V and A105V/I109V substitutions found in replicon cells
contributed directly to the reduced susceptibility to rupintrivir in the FRET assay (Fig. 3C
and D). Notably, we found that the GI A105V mutant protease also showed reduced
susceptibility to rupintrivir, suggesting that, at least in the context of the GI protease,
the A105V substitution may affect the interaction with rupintrivir. In contrast, the
A105V substitution in the GV protease had no appreciable impact on susceptibility to
rupintrivir, which was consistent with results obtained using in vitro translation (Fig. 3D
and 4). These results indicate that the A105 residue in GV protease is unlikely to be
involved in the interaction with rupintrivir. This hypothesis was supported by the IC50s
of the GV A105V/I109V double mutant, which were comparable to those of the GV
I109V single mutant (Fig. 3D). Surprisingly, no signiﬁcant differences in the inhibitory
effects of rupintrivir were observed between the WT GII protease and proteases
carrying any of the mutations. In addition, the susceptibility of the GII protease to
rupintrivir was substantially lower than that of the GI and GV WT proteases. These
ﬁndings suggest that the GII protease has a weaker afﬁnity for rupintrivir than the GI
and GV proteases, probably because the binding site is less conserved and the effects
of susceptibility to rupintrivir by amino acid substitution are different among the
different genotypes.
We obtained similar changes in sensitivity to rupintrivir when the mutations were
introduced into the recombinant MNV clones, where the MNV clone with the I109V
mutation showed reduced susceptibility to rupintrivir in cell culture but viral ﬁtness was
not overtly affected. Surprisingly, while the I109V mutant was readily recovered using
two different reverse genetics approaches, mutants with the A105V and A105V/I109V
substitutions were not viable (Fig. 6). Our FRET assays and in vitro translations assays
conﬁrmed that the mutants with the single substitution A105V and the double sub-
stitution A105V/I109V had no defect in protease activity per se (Fig. 3A and 4),
suggesting that the inability to recover viable virus may be related to some other
function of the protease. While the other functions that the HuNoV protease plays in
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the viral life cycle have yet to be fully elucidated, previous work has demonstrated that
the HuNoV protease has RNA binding activity (32), as well as the ability to cleave
cellular protease substrates (33). Work on the closely related poliovirus protease has
also identiﬁed a phosphoinositide binding domain (34), but it remains to be deter-
mined whether the A105V mutation affects either of these or other as yet to be
identiﬁed functions. It is noteworthy that the A105V mutation was not detected in
isolation and was found only in combination with I109V. While it was outside the scope
of the current study, it may be possible to use the MNV infectious culture system to
generate secondary mutations in other NS proteins that could compensate for the
A105V change introduced in the protease.
Although the crystal structures of proteases from different strains of norovirus are
available (19, 21, 35, 36), in the absence of any crystal structure of a norovirus protease
in complex with rupintrivir, the impact of these amino acid substitutions remains
unclear. The crystal structure of the Norwalk virus protease revealed that the I109
residue is positioned in the S2 pocket, which is formed by residues I109, Q110, R112,
and V114, and also the S4 pocket, which is formed by residues M107, I109, T161, T166,
and V168 and which is considered to be involved in hydrophobic interactions with a
substrate or rupintrivir (21, 36). In addition, the essential role of I109 of the S2 pocket
in the binding of both P2 and P4 residues has previously been reported (22). The S2
pocket of the protease is also known to undergo conformational changes in response
to the binding substrates (21). We therefore modeled the complex of the GI protease
with rupintrivir based on the crystal structure of the HRV2 proteases (Fig. 2C) (10, 21).
The structural alignments suggest that the GI and GII I109V substitution may affect the
hydrophobic interactions of protease with rupintrivir. The mechanism of rupintrivir
resistance generated in poliovirus appears to be somewhat similar, as the G128Q
substitution in a ﬂexible loop of the poliovirus 3C protease has a similar impact on
susceptibility to rupintrivir (Fig. 2B) (23). Like the E3G and A103V substitutions in the 3C
protease of rupintrivir-resistant HRV2, the A105V substitution was not located close to
a location of the interaction of protease with rupintrivir (Fig. 2B) (25). These results may
imply that these substitutions are not the primary mutations conferring resistance but
are in fact secondary mutations. Moreover, despite the accumulation of multiple amino
acid substitutions, high-level resistance to rupintrivir did not occur. This highlights the
suggestion that there is a signiﬁcant barrier to rupintrivir resistance, further supporting
the possibility that viral protease is a potential therapeutic antiviral target for norovi-
ruses.
In conclusion, we successfully identiﬁed, for the ﬁrst time, a protease inhibitor-
resistant HuNoV replicon, indicating at least one potential route to rupintrivir resis-
tance. Furthermore, we demonstrated that rupintrivir has a relatively high genetic
barrier, adding further support to the use of protease inhibitors as potential therapeu-
tics against noroviruses.
MATERIALS AND METHODS
Cells. A human gastric tumor-1 (HGT-1) cell line (29) was used to establish a human norovirus
replicon-harboring HGT (HGT-NV) cell line. In brief, viral protein genome (VPg)-linked RNA was isolated
from BHK cells containing the Norwalk virus GI replicon and transfected into HGT-1 cells. HGT-NV replicon
cells were selected in G418 (1 mg/ml), and limiting dilution was used to identify a clone with high viral
RNA levels. The generated HGT-NV replicon cells were grown and maintained under G418 selection. The
replicon-containing BHK cell line was generated by the transfection of in vitro-transcribed capped RNA
from the cDNA construct of the Norwalk virus replicon (9), kindly provided by Kim Green (National
Institutes of Health, Bethesda, MD, USA), into baby hamster kidney cells. Human embryonic kidney
HEK293T cells were obtained from ATCC. The murine microglial BV-2 cell line was provided by Jennifer
Pocock (University College London, London, UK). BSR-T7 cells (baby hamster kidney cells engineered to
express T7 polymerase) were provided by Karl-Klaus Conzelmann (Ludwig Maximilian University, Munich,
Germany). Cells were maintained in complete Dulbecco’s minimal essential medium (DMEM) containing
10% fetal bovine serum, penicillin (100 units/ml), streptomycin (100 g/ml), and, in the case of HGT-NV
and BSR-T7 cells, G418 (0.5 mg/ml).
Compounds. Rupintrivir and 2-C-methylcytidine (2CMC) were purchased from Sigma-Aldrich and
dissolved in dimethyl sulfoxide (DMSO). A ﬁnal DMSO concentration of 1% was used in all cell culture
experiments in this study.
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Plasmids. The generation of plasmids expressing norovirus protease from GI.1 (M87661), GII.4
(DQ658413), or GV (DQ285629) norovirus and FRET assay constructs has been described previously (18).
The plasmids carrying GI, GII, and GV proteases with the A105V, I109V, or A105V/I109V mutation were
generated from the wild-type (WT) protease constructs described above by the QuikChange site-directed
mutagenesis method. Mutant MNV genomes for reverse genetics were generated by two-step PCR
mutagenesis of the WT MNV genome (pT7 MNV 3RZ) construct as described previously (27). The primers
used for generation of the plasmids are listed in Tables S1 and S2 in the supplemental material.
Inhibitory effect of rupintrivir on viral replication in replicon cells. The inhibitory effect of
rupintrivir on HuNoV replication was assessed by quantiﬁcation of the levels of GI NuNoV RNA and
-actin RNA as the reference gene. Brieﬂy, HGT-NV cells were plated into 96-well plates at a density of
5  103 cells/well in complete DMEM without G418 and then incubated for 24 h in a CO2 incubator at
37°C. After incubation, serial dilutions of rupintrivir were added to the cells, and then the cells were
incubated for 72 h. After incubation, the supernatant was removed and the cells were washed with
phosphate-buffered saline (PBS), and then total RNA was extracted using a GenElute system (Sigma-
Aldrich). The real-time quantitative reverse transcription-PCR (qRT-PCR) assay was performed by using a
One-Step Plus qRT-PCR kit according to the protocol of the manufacturer (Primer Design). Cycling
conditions were reverse transcription at 55°C for 30 min and initial denaturation at 95°C for 5 min,
followed by 40 cycles of denaturation at 95°C for 15 s and annealing and extension at 60°C for 1 min
(ViiA 7 real-time PCR system; Applied Biosystems, USA). The sequences of the primers and probes
that were used for qRT-PCR are as follows (10, 37): for GI HuNoV RNA, 5=-CGY TGG ATG CGN TTY CAT
GA-3= for the forward primer, 5=-CTT AGA CGC CAT CAT CAT TYA C-3= for the reverse primer, and
5=-FAM-AGA TCG CGG TCT CCT GTC CA-TAMRA-3= (where FAM is 6-carboxyﬂuorescein and TAMRA is
6-carboxytetramethylrhodamine) for the probe, and for human -actin RNA, 5=-GGC ATC CAC GAA ACT
ACC TT-3= for the forward primer, 5=-AGC ACT GTG TTG GCG TAC AG-3= for the reverse primer, and
5=-HEX-ATC ATG AAG TGT GAC GTG GAC ATC CG-TAMRA-3= (where HEX is 6-carboxy-2,4,4,5,7,7-
hexachloroﬂuorescein) for the probe. Relative quantiﬁcation was performed using the 2ΔΔCT threshold
cycle (CT) method (38). The 50% effective concentration (EC50) values of rupintrivir were calculated using
XLﬁt (version 5.3) software.
Cell cytotoxicity of rupintrivir in replicon cells. The cell cytotoxicity of rupintrivir against HGT-NV
cells was determined by a resazurin assay (39). Brieﬂy, subconﬂuent HGT-NV cells in 96-well plates were
treated with various concentrations of rupintrivir and then incubated for 72 h in a CO2 incubator at 37°C.
After incubation, the supernatant was removed and the cells were washed with PBS, and then complete
DMEM containing resazurin (0.1 mg/ml) was added to the cells. After 4 h of incubation, the optical
density at 560 nm with a 620-nm optical density reference was determined by using a SpectraMax i3
instrument (Molecular Devices). The 50% cytotoxic concentration (CC50) values of rupintrivir were
calculated using XLﬁt (version 5.3) software.
Colony formation assays. HGT-NV cells treated with rupintrivir or DMSO for 12 days in the absence
of G418 were plated into 6-well plates in complete DMEM and maintained without rupintrivir in the
presence of G418 (1.5 mg/ml). After 1 week of incubation, the colonies on the plate were stained with
0.1% toluidine blue and photographed.
Sequence analysis. Total RNA was puriﬁed from replicon cells by using a GenElute system (Sigma-
Aldrich), and then cDNA was synthesized from the RNA by using Moloney murine leukemia virus reverse
transcriptase (Invitrogen) and a random hexamer. The protease-coding region was ampliﬁed by PCR with
Taq DNA polymerase (Invitrogen) and the speciﬁc primers listed in Table S3. The ampliﬁed DNA was
sequenced in an Applied Biosystems 3730xl DNA analyzer. The sequences of the protease-coding region
from rupintrivir-resistant replicon cells were compared with those from the replicon cells treated with
DMSO, and amino acid substitutions were analyzed.
Cell-based FRET assay. The YFP/CFP ratio was used to determine FRET efﬁciency, as described
previously (18, 40). Brieﬂy, HEK293T cells were plated into black 96-well cell culture microplates (Greiner
Bio-One) at a density of 5  104 cells/well in 100 l of DMEM containing 10% fetal bovine serum with
or without various concentrations of rupintrivir and then incubated for 4 h in a CO2 incubator at 37°C.
After incubation, the cells were transfected with 0.1 g of protease and 0.1 g of the appropriate FRET
construct by transfection with the Lipofectamine 2000 reagent according to the manufacturer’s protocol
(Invitrogen) and then incubated for 24 h. After incubation, the medium was removed and replaced with
PBS. The plates were then analyzed on a SpectraMax i3 instrument in ﬂuorescence mode, with excitation
set at 434 nm and the reading emissions set at 477 nm (CFP) and 527 nm (YFP). The background
ﬂuorescence from wells transfected with pcDNA3.1 was determined and subtracted. The 50% inhibitory
concentration (IC50) values of rupintrivir were calculated using XLﬁt (version 5.3) software.
Reverse genetics of MNV. Reverse genetics rescues of WT or mutant MNV (with the A105V, I109V,
and A105V/I109V mutations in protease NS6) were performed by two methods as described previously
(27, 41). Brieﬂy, BSR-T7 cells were infected with recombinant fowlpox virus expressing T7 polymerase. At
3 h postinfection, the cells were transfected with plasmids containing the MNV genome, either the WT
MNV genome or the genomes of the various mutant MNV constructs, under the control of a T7 promoter.
In the case of the RNA-based MNV reverse genetics system, BSR-T7 cells seeded 24 h prior to transfection
were typically transfected with capped in vitro-synthesized MNV RNA. At 24 h posttransfection, the cells
were frozen at 80°C for viral titer determination or processed for repetitive passages. The viral titer was
determined from the 50% tissue culture infective dose (TCID50) in BV-2 cells. Repetitive passage was also
performed with the supernatant of BSR-T7 cells transfected with the MNV plasmid in BV-2 cells. At 48 h
postinoculation, the supernatant of BV-2 cells was inoculated onto BV-2 cells. Virus was passaged in BV-2
cells a further two times. After three passages, the supernatants were inoculated onto BV-2 cells and the
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increase in RNA level (the RNA level at 12 h postinoculation minus the RNA level at 1 h postinoculation)
was determined by qRT-PCR. The sequences of the primers and probes that were used for qRT-PCR of
MNV RNA are as follows (42): 5=-CCG CAG GAA CGC TCA GCA G-3= for the forward primer, 5=-GGY TGA
ATG GGG ACG GCC-3= for the reverse primer, and 5=-FAM-ATG AGT GAT GGC GCA-TAMRA-3= for the
probe.
Antiviral effects of compounds against MNV infection. BV-2 cells were infected with recombinant
WT MNV or the MNV I109V mutant at an MOI of 0.1 or 1 for 1 h in the CO2 incubator at 37°C. After
incubation, the supernatant was removed and the cells were washed twice with PBS, and then complete
DMEM containing various concentrations of rupintrivir or 2CMC was added to the cells. After 24 h for
incubation, the virus titers of the supernatant were determined by measurement of the TCID50. On the
basis of the TCID50, the 90% effective concentration (EC90) values of rupintrivir and 2CMC were calculated
using XLﬁt (version 5.3) software.
Western blot analysis. Anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase; catalog number
AM4300), anti-green ﬂuorescent protein (GFP; catalog number ab290), and anti-mCherry (catalog num-
ber LS-C204825) antibodies were purchased from Ambion, Abcam, and LifeSpan BioSciences, respec-
tively. IRdye 800 secondary antibodies were purchased from LI-COR. HEK293T cells cotransfected with the
GI, GII, or GV NS1/2-NS3 FRET sensor and protease were lysed in radioimmunoprecipitation assay buffer
(50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS). Protein concentrations
were determined by use of a Pierce bicinchoninic acid protein assay kit. Samples were separated by
SDS-PAGE using 12.5% polyacrylamide gels and transferred to 0.2-m-pore-size nitrocellulose mem-
branes. Blocking and staining steps were carried out in 5% nonfat dried milk in PBS containing 0.2%
Tween 20. Membranes were imaged through detection of far-red ﬂuorescence on a LI-COR Odyssey
imager.
In vitro translation assay. In vitro translation reactions were performed using a Flexi rabbit
reticulocyte lysate system (Promega). The reaction mixtures were prepared according to the manufac-
turer’s instructions as described for capped mRNAs and programmed with 1 g of RNA per 25-l reaction
mixture. The reaction mixtures were incubated at 30°C for 90 min prior to the addition of an equal
volume of SDS-PAGE sample buffer. Samples were subsequently resolved on a 12.5% SDS-polyacrylamide
gel before exposure to a phosphorimager screen.
Structural comparison and alignments of protease. The crystal structure of the protease of HuNoV
GI (PDB accession number 2IPH) (19), MNV GV (PDB accession number 4ASH) (20), or poliovirus (PV) (PDB
accession number 4DCD) (24) was aligned to the human rhinovirus 2 (HRV2) protease crystal structure
(PDB accession number 1CQQ) (26). Residues A105 and I109 in the GI and GV proteases, residues N165,
E3, and A103 in the HRV2 protease, and residue G128Q in the PV protease involved in rupintrivir
resistance are shown as sticks and in red in Fig. 2. The catalytic residues C139 (GI), A139 mutated from
cysteine (GV), C147 (PV), and C147 (HRV2) are indicated in orange in Fig. 2. The crystal structure of the
GI, GV, or PV protease was aligned to the HRV2 protease crystal structure in complex with rupintrivir and
is shown as the hydrophobic surface of each protease with rupintrivir (cyan) in Fig. 2. All structure
alignments and comparisons were performed using the PyMOL molecular graphics program.
Statistical analysis. Statistical comparisons employed parametric evaluation using one-way analysis
of variance or Student’s t test in GraphPad Prism (version 6) software. P values below 0.05 were
considered statistically signiﬁcant.
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